The A4M Clinical Decision Support Tool (CDST) improves the definition, diagnosis, measurement, and management of hypertension.
Definition & Measurement- A4M uses twice-a-day home blood pressure monitoring to define hypertension. This eliminates white coat HTN and detects masked HTN. We use peak diurnal home blood pressure readings to approximate the highest blood pressure levels over a 10-day time frame to measure BP load, the time burden of hypertension. A BP flow chart tracks your progress over time and relays rates of control to your provider.
Diagnosis- We use a nine-category renin/aldosterone diagnostic Matrix (low renin-low aldosterone HTN to high renin – high aldosterone HTN) to sort over 50 secondary causes of HTN and direct disease specific therapy. The matrix also helps with prognosis (poorer outcomes at the same level of BP control). We use a proprietary drug sequencing algorithm to match the mechanism of hypertension to the mechanism of action of the antihypertensive drugs in those without a determined secondary cause of HTN.
Time Management- We use templated virtual visits to reduce provider management time by up to 75%.
Quality Improvement- We provide performance monitoring to determine best practices, relative drug cost, time management, disease distribution rates, drug side effect rates, event rates and outcomes over time. As the database grows, machine learning will refine the algorithms for improved efficacy and further cost reductions.